gallbladder disease and semaglutide Disease: Safety Guide Understanding the Link Between Weight

The structure highlights the dual-agonist design: a GIP-based backbone (cyan/blue tones) with GLP-1 receptor-engaging modifications, and the C-20 fatty diacid chain extending from the acylated Lys20 that enables once-weekly dosing

Zhou G, Xu Y, Zhai Y, Gong Z, Xu K, Wang G, et al

Results extend beyond diabetes reversal to other areas of metabolic and cardiovascular health, with sustained improvements in blood pressure, inflammation, liver function, and BMI

Notably, a cross-over study did not demonstrate non-inferiority of lerodalcibep compared to Repatha in patients with HoFH and clinical data comparing lerodalcibep and Praluent have not been published

This is a general reference only, and actual prescribing decisions are made by a licensed provider based on individual health history